Connected pumps
iLet Bionic Pancreas
The iLet Bionic Pancreas reduces the need to make decisions about your diabetes management by automatically adjusting to your insulin needs based on your Dexcom CGM readings. Setup is easy with only your weight required to get started, and as the iLet learns about you, no carb counting * and no corrections are needed.
*User must be carb aware.
The Tubeless Omnipod® 5 Automated Insulin Delivery System
The only tubeless automated insulin delivery system that integrates with Dexcom CGM. Omnipod 5 is a waterproof,† wearable alternative to traditional pumps. SmartAdjust™ technology proactively helps to correct high and protect from low glucose levels.4,5
Pod shown without the necessary adhesive. *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof.
The Tandem Mobi System
Tandem Mobi is powered by Control-IQ technology, which predicts and helps prevent highs and lows. It’s fully controllable with a compatible, personal iPhone,‡ offers wearability like never before, and integrates with the Dexcom G7 and G6 sensors — creating an impressively small automated insulin delivery system.
Tandem t:slim X2TM insulin pump
The t:slim X2 insulin pump with Control-IQ technology predicts and helps prevent highs and lows. Pump users enjoy advanced bolus features, Personal Profiles, multiple infusion set options, and more. The pump seamlessly connects to an integrated care platform bringing together the data, treatment, and support needed to better manage diabetes.
"Delaney was diagnosed with type 1 at age 3. Thanks, Omnipod and Dexcom, for changing our lives and helping keep our girl as healthy as possible."
- Parents of Delaney W., Dexcom Warrior
Meet our CGM family
Dexcom G6 and Dexcom G7 offer powerful glucose monitoring that’s made for connections, letting you view your glucose data on any compatible smart device.‡
Our experts are here to help.
‡For a list of compatible devices, visit www.Dexcom.com/compatibility.
1 Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717. 2 Brown SA et al. Diabetes Care. 2021;44(7):1630-1640. 3 Russell SJ, et al. N Engl J Med. 2022;387(13):1161-1172. 4 Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/adolescents and children, standard therapy vs. 3-mo Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et al. Diabetes Care (2021). 5 Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose (>180mg/dL) from CGM in standard therapy vs Omnipod 5 = 39.4% vs. 29.5%. Average time with low blood glucose (<70mg/dL) from CGM in standard therapy vs Omnipod 5 = 3.41% vs. 2.13%. Sherr JL, et al. Diabetes Care (2022).
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.